Zeynep ����klar: Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, T��rkiye ORCID
Merih Berbero��lu: Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, T��rkiye ORCID
Sirmen K��z��lcan ��etin: Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, T��rkiye ORCID
Melek Y��ld��z: ��stanbul University-��stanbul Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
Serap Turan: Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
����kran Darcan: Ege University Faculty of Medicine, Department of Pediatric Endocrinology, ��zmir, T��rkiye ORCID
Semra ��etinkaya: University of Health Sciences T��rkiye, Ankara Dr. Sami Ulus Child Health and Diseases Health Implementation and Research Center, Ankara, T��rkiye ORCID
Nihal Hatipo��lu: Erciyes University Faculty of Medicine, Department of Pediatric Endocrinology, Kayseri, T��rkiye ORCID
Korcan Demir: Dokuz Eyl��l University Faculty of Medicine, Department of Pediatric Endocrinology, ��zmir, T��rkiye ORCID
��znur Vermezo��lu: Trakya University Faculty of Medicine, Department of Pediatric Endocrinology, Edirne, T��rkiye ORCID
Zehra Yava�� Abal��: Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
Deniz ��zalp K��z��lay: Ege University Faculty of Medicine, Department of Pediatric Endocrinology, ��zmir, T��rkiye ORCID
Nilay G��rkem Erdo��an: University of Health Sciences T��rkiye, Ankara Dr. Sami Ulus Child Health and Diseases Health Implementation and Research Center, Ankara, T��rkiye ORCID
��lk�� G��l ��iraz: Erciyes University Faculty of Medicine, Department of Pediatric Endocrinology, Kayseri, T��rkiye ORCID
Zerrin Orbak: Atat��rk University Faculty of Medicine, Department of Pediatric Endocrinology and Diabetes, Ankara, T��rkiye ORCID
��lker Tolga ��zgen: Biruni University Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
Aysun Bideci: Gazi University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, T��rkiye ORCID
Beray Selver Eklio��lu: Necmettin Erbakan University Faculty of Medicine, Department of Pediatric Endocrinology, Konya, T��rkiye ORCID
Esin Karak��l���� ��zturan: Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
G��rkan Tar����n: Adana City Training and Research Hospital, Clinic of Pediatric Endocrinology Adana, T��rkiye ORCID
Abdullah Bereket: Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
Feyza Darendeliler: ��stanbul University-��stanbul Faculty of Medicine, Department of Pediatric Endocrinology, ��stanbul, T��rkiye ORCID
Objective: Proportional short stature is one of the most important features of Noonan syndrome (NS), and adult height often remains below the third percentile. Although the pathophysiology of short stature in NSpatients is not fully understood, it has been shown that growth hormone (GH) treatment is beneficial in NS, significantly improving height in respect to the results of short and long-term GH treatment. Methods: In this national retrospective cohort study, patients with NS who reached final height from 14 centers were evaluated. patients were stratified by sex and treatment with or without GH and final height outcomes were compared. Results: The study included 67 patients with NS, of whom 53 (79.1%) with mean follow-up 5.6 years, received GH treatment. At presentation height standard deviation scores (SDS) of the subjects who were started on GH tended to be shorter than those who did not (-3.26��1.07 vs. -2.53��1.23). In girls mean final height and final height SDS in those using GH vs not using GH were 150.1 cm (-2.17 SDS) vs. 147.4 cm (-2.8 SDS), respectively, and for boys these values were 162.48 cm (-1.81 SDS) vs 157.46 cm (-2.68 SDS), respectively. The ��height SDS value of the cases was significantly higher in the group receiving GH compared to those not receiving GH (1.36��1.12 SD vs. -0.2��1.24, p<0.001). Cardiac findings remained stable in two patients with hypertrophic cardiomyopathy who received GH treatment. No significant side effects were observed in any patient during follow-up. Conclusion: In patients with NS who reach their final height, a significant increase in height was observed with GH treatment. An increase of approximately +1.4 SDS may be achieved. GH treatment appears to be safe and effective in NS.
